The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

PURPOSE: Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of high-grade serous ovarian cancers (HGSOCs). Therapeutic resistance, resulting from restoration of homologous recombination (HR) repair or replication fork stabilization, is a pressing clinical problem. We asses...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: Parmar, Kalindi, Kochupurakkal, Bose S., Lazaro, Jean-Bernard, Wang, Zhigang C., Palakurthi, Sangeetha, Kirschmeier, Paul T., Yang, Chunyu, Sambel, Larissa A., Farkkila, Anniina, Reznichenko, Elizaveta, Reavis, Hunter D, Dunn, Connor E., Zou, Lee, Do, Khanh T., Konstantinopoulos, Panagiotis A., Matulonis, Ursula A., Liu, Joyce F., D’Andrea, Alan D., Shapiro, Geoffrey I.
Format: Artigo
Sprog:Inglês
Udgivet: 2019
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6801076/
https://ncbi.nlm.nih.gov/pubmed/31409614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0448
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker